Neurocrine Biosciences | NBIX - Assets


Neurocrine Biosciences reported $4.63B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
ALKERMES USD 2.33B 76.7M Sep/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Amgen USD 90.59B 445M Dec/2025
Biogen USD 29.44B 232M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Cytokinetics USD 1.44B 210.92M Sep/2025
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Exelixis USD 2.84B 20.87M Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
Halozyme Therapeutics USD 2.53B 304.09M Dec/2025
Incyte USD 6.96B 627.62M Dec/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Nektar Therapeutics USD 301.35M 93.81M Sep/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
Prothena USD 352.63M 46.44M Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Repligen USD 2.92B 22.08M Sep/2025
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
Teva Pharmaceutical Industries USD 40.75B 892M Dec/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025
Xoma USD 263.15M 39.7M Sep/2025